<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the acute management of non-ST-elevation acute coronary syndromes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the acute management of non-ST-elevation acute coronary syndromes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the acute management of non-ST-elevation acute coronary syndromes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Simons, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey A Breall, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James Hoekstra, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Unstable angina (UA), acute non-ST-elevation myocardial infarction (NSTEMI), and acute ST-elevation myocardial infarction (STEMI) are the three presentations of acute coronary syndromes (ACS). The first step in the management of patients with ACS is prompt recognition, since the beneficial effects of therapy are greatest when performed soon after hospital presentation. For patients presenting to the emergency department with chest pain suspicious of an ACS, the diagnosis of MI can be confirmed by the electrocardiogram and serum cardiac biomarker elevation; the history is relied upon heavily to make the diagnosis of unstable angina. (See  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department"</a>.)</p><p>Once the diagnosis of either UA or an acute NSTEMI is made, the acute management of the patient involves the simultaneous achievement of several goals:</p><p class="bulletIndent1"><span class="glyph">●</span>Relief of ischemic pain. (See <a class="local">'Initial medical therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of the patient's hemodynamic status and correction of abnormalities. Hypertension and tachycardia, both of which will markedly increase myocardial oxygen consumption requirements, may be managed with beta blockers and intravenous <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Estimation of risk. (See <a class="local">'Early risk stratification'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Choice of a management strategy, ie, an early invasive strategy (with angiography and intent for revascularization with percutaneous coronary intervention [PCI] or coronary artery bypass graft surgery as defined by the anatomy) versus a conservative strategy with medical therapy. (See <a class="local">'Choosing a revascularization strategy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initiation of antithrombotic therapy (including antiplatelet and anticoagulant therapies) to prevent further thrombosis of or embolism from an ulcerated plaque.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta blocker therapy to prevent recurrent ischemia and life-threatening ventricular arrhythmias.</p><p></p><p>The acute management goals should be followed by the administration of different drugs that may improve the long-term prognosis. Some of these therapies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Long-term antiplatelet therapy to reduce the risk of recurrent coronary artery thrombosis or, with PCI, coronary artery stent thrombosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Statins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term oral anticoagulation in the presence of left ventricular thrombus or chronic atrial fibrillation to prevent embolization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible use of an angiotensin converting enzyme inhibitor in patients at increased risk.</p><p></p><p>This topic will summarize emergent/early management issues for patients with UA or acute NSTEMI and then direct the reader to a more detailed discussion in other topics. The management of the patient after a revascularization strategy has been chosen and carried out is discussed separately. (See  <a class="medical medical_review" href="/d/html/48.html" rel="external">"Overview of the nonacute management of unstable angina and non-ST-elevation myocardial infarction"</a>.)</p><p>The management of the patient with STEMI or with a complication of an acute MI (eg, cardiogenic shock, mitral regurgitation, ventricular septal defect) is discussed separately. (See  <a class="medical medical_review" href="/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/83.html" rel="external">"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/63.html" rel="external">"Acute myocardial infarction: Mechanical complications"</a> and  <a class="medical medical_review" href="/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>An increasing number of centers use structured algorithms, checklists, or critical pathways to screen patients with a suspected ACS  (<a class="graphic graphic_algorithm graphicRef52942" href="/d/graphic/52942.html" rel="external">algorithm 1</a>) [<a href="#rid1">1-6</a>]. Many of these strategies combine diagnostic evaluation, such as electrocardiography and serum biomarkers, with therapeutic interventions, such as <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, beta blockers, antithrombotic agents, and, in most patients, early coronary angiography and revascularization. (See  <a class="medical medical_review" href="/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Definitions</span><span class="headingEndMark"> — </span>Among patients considered to have angina, there are three presentations of angina that suggest an ACS:</p><p class="bulletIndent1"><span class="glyph">●</span>Rest angina, which is usually more than 20 minutes in duration</p><p class="bulletIndent1"><span class="glyph">●</span>New onset angina that markedly limits physical activity</p><p class="bulletIndent1"><span class="glyph">●</span>Increasing angina that is more frequent, longer in duration, or occurs with less exertion than previous angina</p><p></p><p>Unstable angina (UA) and acute NSTEMI differ primarily in whether the ischemia is severe enough to cause sufficient myocardial damage to release detectable quantities of a marker of myocardial injury (troponins):</p><p class="bulletIndent1"><span class="glyph">●</span>UA is considered to be present in patients with ischemic symptoms suggestive of an ACS and no elevation in troponins, with or without electrocardiogram changes indicative of ischemia (eg, ST-segment depression or transient elevation or new T-wave inversion).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NSTEMI is considered to be present in patients having the same manifestations as those in UA, but in whom an elevation in troponins is present.</p><p></p><p>Since an elevation in troponins may not be detectable for hours after presentation, UA and NSTEMI are frequently indistinguishable at initial evaluation. As a consequence, initial management is the same for these two syndromes. For this reason, and because the pathogenic mechanisms of the two conditions are similar, they are often considered together. (See  <a class="medical medical_review" href="/d/html/43.html" rel="external">"Acute coronary syndrome: Terminology and classification"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Older patients</span><span class="headingEndMark"> — </span>Our approach to the management of older patients with non-ST-elevation ACS (NSTEACS) is broadly similar to that in younger individuals. Adjustments to treatment may be made based on the patients' general health, weight, and renal function.</p><p>It is estimated that 60 to 65 percent of MIs occur in patients ≥65 years of age and 33 percent occur in patients ≥75 years of age [<a href="#rid7">7,8</a>]. In addition, as many as 80 percent of all deaths related to MI occur in persons ≥65 years of age.</p><p>Although patients age 75 and older have been underrepresented in clinical trials of ACS, the following observations concerning acute MI in older adults compared to younger patients are generally accepted [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Older patients are more likely to have an NSTEMI rather than a STEMI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Older patients more frequently have an atypical presentation, including silent or unrecognized MI due to presenting symptoms of syncope, weakness, or confusion (delirium) [<a href="#rid9">9,10</a>]. Delays in diagnosis have been well-documented and often lead to delays in therapy [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients ≥75 years of age have a higher in-hospital mortality (19 versus 5 percent in one series) [<a href="#rid11">11</a>]. Both bleeding and recurrent MI are also more frequent [<a href="#rid9">9</a>]. (See <a class="local">'Importance of dosing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Older patients are more likely to have heart failure associated with the MI (40 versus 14 percent in one report), the risk for which increases progressively in each successive age group from 36 percent in those 65 to 69 years of age to 65 percent in those ≥85 years of age [<a href="#rid12">12</a>].</p><p></p><p>Some of the worse outcomes after acute MI probably result from comorbidities in older patients, but also can be attributed in part to a lower likelihood of receiving potentially beneficial therapies due to concerns about toxicity. Therapies such as beta blockers, percutaneous coronary intervention, or coronary artery bypass grafting are all utilized to a lesser degree in older patients [<a href="#rid11">11-13</a>].</p><p>A retrospective review of almost 57,000 patients with an NSTEACS found that after adjustment, patients (including those ≥75 years of age) who received more recommended therapies had lower in-hospital mortality rates than those who did not [<a href="#rid14">14</a>]. Thus, although concern about risks and side effects is appropriate and it is not clear that adjustment accounted for all risk factors, older age alone should not be an indication to withhold recommended therapy.</p><p class="headingAnchor" id="H84327499"><span class="h2">Women</span><span class="headingEndMark"> — </span>The approach to women and men should be the same, despite the fact that women have more atypical symptoms, are older, have greater delays to presentation, and have higher prevalence of hypertension [<a href="#rid15">15</a>]. In addition, they are at higher risk of bleeding.</p><p>While most women who present with an ACS will have acute plaque rupture as the cause, other entities such as myocarditis, aortic dissection, or stress-induced cardiomyopathy should be considered (see  <a class="medical medical_review" href="/d/html/3494.html" rel="external">"Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy", section on 'Clinical manifestations'</a>). In a one-year study of 323 women 45 years or older presenting to a community hospital who were diagnosed with an acute MI (including an elevated troponin), 5.9 percent met criteria for stress-induced cardiomyopathy [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Cocaine-associated myocardial infarction</span><span class="headingEndMark"> — </span>MI is a well-described complication among patients presenting with cocaine-induced ischemic symptoms. Beta blockers should be avoided due to the possibility of exacerbation of coronary artery vasoconstriction in the setting of acute MI in patients whose MI might have been triggered by cocaine. (See  <a class="medical medical_review" href="/d/html/4953.html" rel="external">"Clinical manifestations, diagnosis, and management of the cardiovascular complications of cocaine abuse", section on 'Reperfusion and revascularization'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">INITIAL MEDICAL THERAPY</span><span class="headingEndMark"> — </span>Patients with unstable angina (UA) or acute NSTEMI should be treated with an early medical regimen similar to that used in an acute STEMI with one exception: There is no evidence of benefit (and possible harm) from fibrinolysis. Initial therapy, which should be instituted within 20 minutes of presentation, is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department", section on 'Immediate emergency department interventions'</a>.)</p><p>Drug metabolism is more likely to be reduced in older patients, particularly with regard to drugs that are excreted by the kidney. Dose adjustment is necessary with glycoprotein IIb/IIIa inhibitors and unfractionated or low molecular weight heparin, but not with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid9">9</a>]. (See <a class="local">'Older patients'</a> above.)</p><p class="headingAnchor" id="H7"><span class="h2">Antiischemic and analgesic therapy</span></p><p class="headingAnchor" id="H8"><span class="h3">Oxygen</span><span class="headingEndMark"> — </span>In patients with STEMI who have an oxygen saturation ≥94 percent and no signs of respiratory distress, we suggest <strong>not </strong>routinely treating with supplemental oxygen. Patients with lower oxygen saturation or respiratory distress should be treated with oxygen as needed.</p><p>The best evidence regarding the possible benefits and harms of supplemental oxygen therapy comes from the DETO2X-AMI registry-based, open-label randomized trial published in 2017 [<a href="#rid17">17</a>]. In this study, 6629 patients with suspected MI and an oxygen saturation of 90 percent or higher were randomly assigned to receive either supplemental oxygen (6 liters per minute for 6 to 12 hours, delivered through an open face mask) or ambient air. There was no difference in the rate of the primary end point of death from any cause within one year (5.0 versus 5.1 percent; hazard ratio [HR] 0.97, 95% CI 0.79-1.21). In addition, there was no difference in the rate of rehospitalization with MI within one year (3.8 versus 3.3 percent; HR 1.13, 95% CI 0.88-1.46). During a median follow-up of 2.1 years, there was no difference in the rate of the composite end point of all-cause death, rehospitalization for MI, or hospitalization for heart failure (11.2 versus 10.8 percent; HR 1.02, 95% CI 0.88-1.17) [<a href="#rid18">18</a>].</p><p>A 2018 meta-analysis of seven studies (n = 7702), in which most of the patients came from DETO2X-AMI, found that the routine use of oxygen did not decrease the individual risks of all-cause death, recurrent ischemia or MI, heart failure, or occurrence of arrhythmia events [<a href="#rid19">19</a>]. The findings in this meta-analysis were consistent with those in a 2016 Cochrane review [<a href="#rid20">20</a>]. </p><p>A pathophysiologic basis for the potential of harm with supplemental oxygen in patients with normoxia has been articulated [<a href="#rid21">21-23</a>]. Hyperoxia, which might occur with the administration of oxygen to normoxic individuals, has been shown to have a direct vasoconstrictor effect on the coronary arteries [<a href="#rid21">21</a>].</p><p>The potential benefit from the use of hyperbaric oxygen therapy was evaluated in a 2015 meta-analysis of six small studies with 665 participants with MI or severe angina. While a reduction in the risk of death was found (relative risk 0.58, 95% CI 0.36-0.92), methodologic limitations of the studies prevent us from having confidence in the use of such therapy [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Nitroglycerin</span><span class="headingEndMark"> — </span>Sublingual <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> is administered to patients presenting with ischemic type chest pain, followed by intravenous nitroglycerin in patients with persistent pain after three sublingual nitroglycerin tablets, hypertension, or heart failure. (See  <a class="medical medical_review" href="/d/html/64.html" rel="external">"Nitrates in the management of acute coronary syndrome"</a>.)</p><p>Nitrates must be used with caution or avoided in settings in which hypotension is likely or could result in serious hemodynamic decompensation, such as right ventricular infarction or severe aortic stenosis. In addition, nitrates are contraindicated in patients who have taken a phosphodiesterase inhibitor for erectile dysfunction within the previous 24 hours. (See  <a class="medical medical_review" href="/d/html/1541.html" rel="external">"Sexual activity in patients with cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/75.html" rel="external">"Right ventricular myocardial infarction", section on 'Optimization of right ventricular preload'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Morphine</span><span class="headingEndMark"> — </span>In the setting of acute MI, intravenous <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> should be avoided if possible and reserved for patients with an unacceptable level of pain since a large but retrospective study suggests its use is associated with an adverse effect on outcome. We give intravenous morphine sulfate at an initial dose of 2 to 4 mg, with increments of 2 to 8 mg repeated at 5- to 15-minute intervals.</p><p>In a study of 57,039 patients enrolled in the CRUSADE Initiative, a nonrandomized, retrospective observational registry of patients with NSTEACS, those treated with <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> (29.8 percent) had a higher adjusted risk of death than those not (odds ratio 1.48, 95% CI 1.33-1.64) [<a href="#rid25">25</a>]. It is possible those patients receiving morphine were at higher risk at baseline but the CRUSADE study suggests caution in its use.</p><p>While the mechanism(s) by which <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> might be associated with decreased survival is not known, at least two studies have raised the possibility that it acts by interfering with the antiplatelet effect of the P2Y<sub>12</sub> receptor blockers (see  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Our approach to early DAPT'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>In the IMPRESSION trial, 70 acute MI patients treated with <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> were randomly assigned to receive intravenous <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> (5 mg) or placebo [<a href="#rid26">26</a>]. Morphine lowered (active) ticagrelor plasma concentration and impaired its antiplatelet effect.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 24 healthy subjects who received a loading dose of 600 mg of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> and either 5 mg of intravenous <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> or placebo, morphine significantly delayed clopidogrel resorption and reduced the area under the curve levels of its active metabolite by 52 percent [<a href="#rid27">27</a>]. Platelet inhibition, as measured by multiple tests, was less pronounced in those given morphine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 50 patients with STEMI undergoing primary percutaneous coronary intervention who were randomly assigned to either <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a>, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> was an independent predictor of high residual platelet reactivity at two hours (odds ratio 5.29, 95% CI 1.44-19.49) [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Timing of initiation'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Beta blockers</span><span class="headingEndMark"> — </span>Controlled trials have repeatedly documented the beneficial effects of beta blockers in patients with acute MI; however, there have been no randomized trials specifically addressing the efficacy of these drugs in NSTEACS.</p><p>Nevertheless, given the proven efficacy in unselected patients with an acute MI and the absence of harm in NSTEMI or UA, we start beta blocker therapy in all patients without contraindications within 24 hours [<a href="#rid15">15</a>]. In our view, treatment should include early use of intravenous beta blockade in patients without contraindications who have ongoing chest pain, hypertension, or tachycardia not caused by heart failure. A cardioselective agent (<a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> or <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a>) is preferred.</p><p>However, based upon the results of the COMMIT/CCS2 trial, the largest placebo-controlled trial ever performed with beta blockers in acute MI, it seems reasonable to defer intravenous beta blockers in patients who are hemodynamically compromised in whom mortality may actually be increased by such therapy. Once the patient is stable, an oral beta blocker can be started with gradual uptitration to the maintenance doses cited below. (See  <a class="medical medical_review" href="/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a>.)</p><p class="headingAnchor" id="H12643985"><span class="h3">Statin therapy</span><span class="headingEndMark"> — </span>For all patients with an acute coronary syndrome (ACS), we recommend high-intensity statin therapy (<a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> 80 mg daily or <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a> 20 or 40 mg daily) regardless of baseline low density lipoprotein-cholesterol level. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome", section on 'Our approach to in-hospital therapy'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Antithrombotic therapy</span></p><p class="headingAnchor" id="H13"><span class="h3">Antiplatelet therapy</span><span class="headingEndMark"> — </span>In the absence of an absolute contraindication, antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and a platelet P2Y<sub>12</sub> receptor blocker is indicated in <strong>all</strong> patients with an NSTEACS [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Anticoagulation</span><span class="headingEndMark"> — </span>For all patients with NSTEACS, we recommend anticoagulant therapy as soon as possible after the diagnosis. (See  <a class="medical medical_review" href="/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes"</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Importance of dosing</span><span class="headingEndMark"> — </span>Excessive dosing of antithrombotic and antiplatelet agents is common and associated with an increase in bleeding risk. This issue is discussed separately. (See  <a class="medical medical_review" href="/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes", section on 'Anticoagulant Use'</a>.)</p><p class="headingAnchor" id="H2206127626"><span class="h2">Transfusion thresholds</span><span class="headingEndMark"> — </span>Red blood cell transfusion is generally reserved for severe or symptomatic anemia, such as hemoglobin &lt;8 g/dL or hemoglobin 8 to 10 g/dL with hemodynamic instability or ongoing ischemia. Clinical judgment is required to determine if transfusion is likely to improve oxygen delivery or if there are other reasons to consider transfusion such as active bleeding or trauma.</p><p>The rationale for using a restrictive transfusion strategy (limiting transfusions, transfusing for a lower rather than a higher hemoglobin level) includes avoiding risks of transfusion reactions or transfusion-transmitted infection and limiting burdens and costs while using evidence-based thresholds for optimal outcomes. While anemia correlates with worse outcomes, this is likely to be an association rather than causation. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Overview of our approach'</a>.)</p><p>Supporting data for the thresholds used in ACS are presented separately. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Acute MI'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Potassium and magnesium</span><span class="headingEndMark"> — </span>There are no clinical trials documenting the benefits of electrolyte replacement in acute MI. We recommend maintaining the serum potassium concentration above 4.0 meq/L and a serum magnesium concentration above 2.0 meq/L (2.4 mg/dL or 1 mmol/L). Much of the evidence for this recommendation was derived from studies before the routine use of beta blocker and the use of reperfusion in many patients. (See  <a class="medical medical_review" href="/d/html/1060.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features", section on 'Ventricular fibrillation'</a>.)</p><p>A 2012 retrospective cohort study found that for patients with acute MI, the lowest mortality was observed in those with post-admission serum potassium values between 3.5 and &lt;4.5 meq/L [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/88759.html" rel="external">"Risk factors for adverse outcomes after ST-elevation myocardial infarction", section on 'Serum potassium'</a>.)</p><p>We suggest that the serum potassium fall within the range of 3.5 to 4.5 meq/L. Some of our reviewers prefer a tighter range of 4.0 to 4.5 meq/L. It may be difficult to lower the potassium below 4.5 meq/L in some patients, such as those with chronic kidney disease.</p><p class="headingAnchor" id="H17"><span class="h2">Nonsteroidal antiinflammatory drugs</span><span class="headingEndMark"> — </span>Nonsteroidal antiinflammatory drugs (except <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>) should be discontinued immediately due to an increased risk of cardiovascular events associated with their use. (See  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a>.)</p><p class="headingAnchor" id="H1151892438"><span class="h2">Intravenous glucose-insulin-potassium</span><span class="headingEndMark"> — </span>We do not recommend the use of intravenous glucose-insulin-potassium (GIK) to improve outcomes in patients with suspected or diagnosed acute MI. Much of the available evidence comes from studies of patients with ST-elevation MI. The discussion of the potential use of GIK in these patients is found elsewhere. (See  <a class="medical medical_review" href="/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction", section on 'Therapies of unclear benefit'</a>.)</p><p>The IMMEDIATE trial randomly assigned 871 patients with suspected ACS (approximately 60 percent without ST-elevation on the presenting electrocardiogram) to intravenous GIK or identical-appearing 5 percent glucose placebo, which was administered by paramedics in the out-of-hospital setting and continued for 12 hours [<a href="#rid30">30</a>]. There was no difference in the rate of progression to MI (as measured by biomarkers and electrocardiogram evidence) at 24 hours or the rate of death at 30 days among patients who received GIK compared to those who received placebo (48.7 versus 52.6 percent; odds ratio 0.88, 95% CI 0.66-1.13 and 4.4 versus 6.1 percent; odds ratio 0.72, 95% CI 0.40-1.29, respectively).</p><p class="headingAnchor" id="H2811512699"><span class="h1">CHOOSING A REVASCULARIZATION STRATEGY</span><span class="headingEndMark"> — </span>In patients with an NSTEMI or unstable angina, management is influenced by the choice of revascularization strategy, which include immediate revascularization (ie, angiography within two hours of presentation), invasive strategy (ie, angiography without prior imaging), and selective angiography (ie, stress or anatomic imaging followed by PCI as indicated). The selection of a revascularization strategy is discussed separately. (See  <a class="medical medical_review" href="/d/html/46.html" rel="external">"Non-ST-elevation acute coronary syndromes: Selecting an approach to revascularization"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">ARRHYTHMIA PREVENTION AND MANAGEMENT</span><span class="headingEndMark"> — </span>Both atrial and ventricular arrhythmias can be seen during and after the acute phase of an acute NSTEMI. These include atrial fibrillation or flutter, which can cause symptomatic hypoperfusion due to a rapid rate, and life-threatening ventricular tachycardia (VT) or ventricular fibrillation (VF). (See  <a class="medical medical_review" href="/d/html/82.html" rel="external">"Supraventricular arrhythmias after myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/1060.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features"</a>.)</p><p>Prophylactic intravenous or intramuscular <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> to prevent VT/VF in the acute MI patient is <strong>not</strong> recommended [<a href="#rid31">31</a>]. Recommended prophylactic measures include early administration of a beta blocker and treatment of hypokalemia and hypomagnesemia. Treatment of ventricular tachyarrhythmias in the setting of acute MI is discussed separately. (See  <a class="medical medical_review" href="/d/html/1060.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">EARLY RISK STRATIFICATION</span><span class="headingEndMark"> — </span>Early risk stratification in patients with acute coronary syndrome (ACS) is essential to identify those patients at highest risk for further cardiac events who may benefit from a more aggressive therapeutic approach [<a href="#rid15">15,32</a>]. Clinical trials have identified a number of factors predicting high risk and a benefit from an early invasive strategy [<a href="#rid33">33-37</a>]. These include the presence and extent of ST segment depression, elevated cardiac biomarkers, evidence of hemodynamic instability, and persistent chest pain despite appropriate medical therapy. These variables have been used to create risk scores such as TIMI, GRACE, and PURSUIT. Using an end point of death or MI at one year, and area under the survival curve (AUC), all three have good predictive ability, with GRACE being somewhat better than PURSUIT and TIMI [<a href="#rid38">38</a>]. Using an end point of death, MI, or urgent revascularization at 30 days and AUC analysis, all three predictors were comparable with TIMI somewhat better than GRACE and PURSUIT [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/76.html" rel="external">"Risk stratification after non-ST elevation acute coronary syndrome"</a>.)</p><p>It should be noted, however, that individual factors in the seven-point TIMI risk score may carry more risk than others, or be more specific for ACS than others. As an example, serum troponin elevation and ST segment depression individually are markers of high risk, regardless of the other TIMI risk factors.</p><p class="headingAnchor" id="H20"><span class="h2">TIMI risk score</span><span class="headingEndMark"> — </span>Analysis of data from the TIMI 11B and ESSENCE trials found that seven variables at presentation were independently predictive of outcome in patients with unstable angina or an acute NSTEMI; a value of one was assigned when a factor was present and 0 when it was absent (<a class="calc calc_professional" href="/d/html/13466.html" rel="external">calculator 1</a>) [<a href="#rid40">40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥65 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of at least three risk factors for coronary heart disease (hypertension, diabetes, dyslipidemia, smoking, or positive family history of early MI).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior coronary stenosis of ≥50 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of ST segment deviation on admission electrocardiogram.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At least two anginal episodes in prior 24 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum cardiac biomarkers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in prior seven days (which is probably a marker for more severe coronary disease) [<a href="#rid41">41</a>].</p><p></p><p>Patients are considered to be at low risk with a score of 0 to 2, intermediate risk with a score of 3 to 4, and high risk with a score of 5 to 7  (<a class="graphic graphic_figure graphicRef67473" href="/d/graphic/67473.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H2809811746"><span class="h2">GRACE risk score</span><span class="headingEndMark"> — </span>The simplified <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.outcomes-umassmed.org%2Fgrace%2F&amp;token=erEtv2h4SKbehy52hBNFQ4C8qBxX5%2BoV2yJv4xO%2BcQuKc9kv1XSieCg%2B%2F7gTuIMn&amp;TOPIC_ID=68" target="_blank">GRACE calculation</a> uses eight parameters to predict death and MI in hospital and at six months: age, heart rate, systolic blood pressure, creatinine, Killip Class congestive heart failure, cardiac arrest, ST segment deviation, and elevated cardiac enzyme markers [<a href="#rid42">42,43</a>].</p><p class="headingAnchor" id="H2851047788"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114034.html" rel="external">"Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115645.html" rel="external">"Society guideline links: Secondary prevention of cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial medical therapy</strong> – Unstable angina (UA) and acute non-ST-elevation myocardial infarction (NSTEMI) are medical emergencies that require the simultaneous application of multiple therapies  (<a class="graphic graphic_algorithm graphicRef52942" href="/d/graphic/52942.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef75032" href="/d/graphic/75032.html" rel="external">table 1</a>). (See <a class="local">'Initial medical therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antiischemic and antithrombotic therapies</strong> – The initial therapy for patients with UA or NSTEMI includes antiischemic and antithrombotic therapies. (See <a class="local">'Antiischemic and analgesic therapy'</a> above and <a class="local">'Antithrombotic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of revascularization strategy</strong> – In patients with UA or NSTEMI, the timing of coronary angiography and revascularization with percutaneous coronary intervention (PCI) are determined by the clinical features, risk factors, and signs of ongoing ischemia. (See  <a class="medical medical_review" href="/d/html/46.html" rel="external">"Non-ST-elevation acute coronary syndromes: Selecting an approach to revascularization"</a>.)</p><p></p><p class="headingAnchor" id="H1208836420"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Julian M Aroesty, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for the evaluation and triage of the chest pain patient. Ann Emerg Med 1997; 29:116.</a></li><li><a class="nounderline abstract_t">Ornato JP. Chest pain emergency centers: improving acute myocardial infarction care. Clin Cardiol 1999; 22:IV3.</a></li><li><a class="nounderline abstract_t">Gibler WB. Evaluation of chest pain in the emergency department. Ann Intern Med 1995; 123:315; author reply 317.</a></li><li><a class="nounderline abstract_t">Cannon CP, Hand MH, Bahr R, et al. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J 2002; 143:777.</a></li><li><a class="nounderline abstract_t">Bassan R, Pimenta L, Scofano M, et al. Probability stratification and systematic diagnostic approach for chest pain patients in the emergency department. Crit Pathw Cardiol 2004; 3:1.</a></li><li><a class="nounderline abstract_t">Herzog E, Saint-Jacques H, Rozanski A. The PAIN pathway as a tool to bridge the gap between evidence and management of acute coronary syndrome. Crit Pathw Cardiol 2004; 3:20.</a></li><li><a class="nounderline abstract_t">Goldberg RJ, McCormick D, Gurwitz JH, et al. Age-related trends in short- and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975-1995). Am J Cardiol 1998; 82:1311.</a></li><li><a class="nounderline abstract_t">Roger VL, Jacobsen SJ, Weston SA, et al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med 2002; 136:341.</a></li><li><a class="nounderline abstract_t">Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115:2549.</a></li><li><a class="nounderline abstract_t">Bayer AJ, Chadha JS, Farag RR, Pathy MS. Changing presentation of myocardial infarction with increasing old age. J Am Geriatr Soc 1986; 34:263.</a></li><li><a class="nounderline abstract_t">Paul SD, O'Gara PT, Mahjoub ZA, et al. Geriatric patients with acute myocardial infarction: Cardiac risk factor profiles, presentation, thrombolysis, coronary interventions, and prognosis. Am Heart J 1996; 131:710.</a></li><li><a class="nounderline abstract_t">Mehta RH, Rathore SS, Radford MJ, et al. Acute myocardial infarction in the elderly: differences by age. J Am Coll Cardiol 2001; 38:736.</a></li><li><a class="nounderline abstract_t">Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA 1996; 275:1104.</a></li><li><a class="nounderline abstract_t">Alexander KP, Roe MT, Chen AY, et al. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005; 46:1479.</a></li><li><a class="nounderline abstract_t">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130:2354.</a></li><li><a class="nounderline abstract_t">Sy F, Basraon J, Zheng H, et al. Frequency of Takotsubo cardiomyopathy in postmenopausal women presenting with an acute coronary syndrome. Am J Cardiol 2013; 112:479.</a></li><li><a class="nounderline abstract_t">Hofmann R, James SK, Jernberg T, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. N Engl J Med 2017; 377:1240.</a></li><li><a class="nounderline abstract_t">Jernberg T, Lindahl B, Alfredsson J, et al. Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction. Circulation 2018; 138:2754.</a></li><li><a class="nounderline abstract_t">Abuzaid A, Fabrizio C, Felpel K, et al. Oxygen Therapy in Patients with Acute Myocardial Infarction: A Systemic Review and Meta-Analysis. Am J Med 2018; 131:693.</a></li><li><a class="nounderline abstract_t">Cabello JB, Burls A, Emparanza JI, et al. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev 2013; :CD007160.</a></li><li><a class="nounderline abstract_t">Moradkhan R, Sinoway LI. Revisiting the role of oxygen therapy in cardiac patients. J Am Coll Cardiol 2010; 56:1013.</a></li><li><a class="nounderline abstract_t">Shuvy M, Atar D, Gabriel Steg P, et al. Oxygen therapy in acute coronary syndrome: are the benefits worth the risk? Eur Heart J 2013; 34:1630.</a></li><li><a class="nounderline abstract_t">Loscalzo J. Is Oxygen Therapy Beneficial in Acute Myocardial Infarction? Simple Question, Complicated Mechanism, Simple Answer. N Engl J Med 2017; 377:1286.</a></li><li><a class="nounderline abstract_t">Bennett MH, Lehm JP, Jepson N. Hyperbaric oxygen therapy for acute coronary syndrome. Cochrane Database Syst Rev 2015; :CD004818.</a></li><li><a class="nounderline abstract_t">Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J 2005; 149:1043.</a></li><li><a class="nounderline abstract_t">Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37:245.</a></li><li><a class="nounderline abstract_t">Hobl EL, Stimpfl T, Ebner J, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63:630.</a></li><li><a class="nounderline abstract_t">Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61:1601.</a></li><li><a class="nounderline abstract_t">Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA 2012; 307:157.</a></li><li><a class="nounderline abstract_t">Selker HP, Beshansky JR, Sheehan PR, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA 2012; 307:1925.</a></li><li><a class="nounderline abstract_t">Martí-Carvajal AJ, Simancas-Racines D, Anand V, Bangdiwala S. Prophylactic lidocaine for myocardial infarction. Cochrane Database Syst Rev 2015; :CD008553.</a></li><li><a class="nounderline abstract_t">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64:e139.</a></li><li><a class="nounderline abstract_t">Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994; 89:1545.</a></li><li><a class="nounderline abstract_t">Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879.</a></li><li><a class="nounderline abstract_t">Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354:708.</a></li><li><a class="nounderline abstract_t">Lagerqvist B, Säfström K, Ståhle E, et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol 2001; 38:41.</a></li><li><a class="nounderline abstract_t">Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000; 356:9.</a></li><li><a class="nounderline abstract_t">de Araújo Gonçalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005; 26:865.</a></li><li><a class="nounderline abstract_t">Lee B, Chang AM, Matsuura AC, et al. Comparison of cardiac risk scores in ED patients with potential acute coronary syndrome. Crit Pathw Cardiol 2011; 10:64.</a></li><li><a class="nounderline abstract_t">Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.</a></li><li><a class="nounderline abstract_t">Borzak S, Cannon CP, Kraft PL, et al. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol 1998; 81:678.</a></li><li><a class="nounderline abstract_t">Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006; 333:1091.</a></li><li><a class="nounderline abstract_t">Tang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J 2007; 153:29.</a></li></ol></div><div id="topicVersionRevision">Topic 68 Version 57.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8998090" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Comprehensive strategy for the evaluation and triage of the chest pain patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10492848" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chest pain emergency centers: improving acute myocardial infarction care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611601" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evaluation of chest pain in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12040337" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18340129" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Probability stratification and systematic diagnostic approach for chest pain patients in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18340134" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The PAIN pathway as a tool to bridge the gap between evidence and management of acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856911" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Age-related trends in short- and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975-1995).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11874305" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502590" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3950299" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Changing presentation of myocardial infarction with increasing old age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8721643" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Geriatric patients with acute myocardial infarction: Cardiac risk factor profiles, presentation, thrombolysis, coronary interventions, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11527626" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute myocardial infarction in the elderly: differences by age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8601930" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16226171" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25249586" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23683950" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Frequency of Takotsubo cardiomyopathy in postmenopausal women presenting with an acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844200" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Oxygen Therapy in Suspected Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30767504" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29355510" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Oxygen Therapy in Patients with Acute Myocardial Infarction: A Systemic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23963794" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Oxygen therapy for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846598" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Revisiting the role of oxygen therapy in cardiac patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23554440" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844195" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Is Oxygen Therapy Beneficial in Acute Myocardial Infarction? Simple Question, Complicated Mechanism, Simple Answer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26202854" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hyperbaric oxygen therapy for acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15976786" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26491112" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24315907" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23500251" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22235086" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Serum potassium levels and mortality in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22452807" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26295202" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prophylactic lidocaine for myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25260718" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8149520" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11419424" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475181" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11451294" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10892758" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764619" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21988945" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of cardiac risk scores in ED patients with potential acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10938172" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9527073" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032691" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17174633" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
